Using genetic technologies to reduce, rather than widen, health disparities

Health Affairs

Volumn 35, Issue 8, 2016, Pages 1367-1373

  Smith, Caren E ^a   Fullerton, Stephanie M ^b   Dookeran, Keith A ^c   Hampel, Heather ^d,e   Tin, Adrienne ^f   Maruthur, Nisa M ^g   Schisler, Jonathan C ^h   Henderson, Jeffrey A ⁱ   Tucker, Katherine L ^j   Ordovás, José M ^k  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d Division of Human Genetics   (United States)

^e Department of Internal Medicine   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ Black Hills Center for American Indian Health   (United States)

^j UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^k TUFTS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CHRONIC KIDNEY DISEASE; ETHNIC DIFFERENCE; FAMILIAL CANCER; GENETIC DATABASE; GENETIC RISK; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HEALTH DISPARITY; HUMAN; KIDNEY DISEASE; MEDICAL ETHICS; PARTICIPATORY RESEARCH; PATIENT EDUCATION; RACE DIFFERENCE; STIGMA; AFRICAN AMERICAN; BREAST TUMOR; CHRONIC KIDNEY FAILURE; ECONOMICS; FEMALE; GENETIC DISORDER; GENETIC SCREENING; HEALTH CARE DISPARITY; HISPANIC; MALE; MINORITY GROUP; NEEDS ASSESSMENT; PROCEDURES; RISK ASSESSMENT; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AFRICAN AMERICANS; BREAST NEOPLASMS; FEMALE; GENETIC DISEASES, INBORN; GENETIC TESTING; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; MALE; MINORITY GROUPS; NEEDS ASSESSMENT; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84982281683     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.1476     Document Type: Article

References (47)

1. Tattersall I. Human origins: out of Africa. Proc Natl Acad Sci USA. 2009;106(38):16018-21.
2. Courtiol A, Pettay JE, Jokela M, Rotkirch A, Lummaa V. Natural and sexual selection in a monogamous historical human population. Proc Natl Acad Sci U S A. 2012;109(21): 8044-9.
3. White House. The Precision Medicine Initiative [Internet]. Washington (DC): White House; [cited 2016 Jun 29]. Available from: https:// www.whitehouse.gov/precisionmedicine
4. Demetriou CA, van Veldhoven K, Relton C, Stringhini S, Kyriacou K, Vineis P. Biological embedding of early-life exposures and disease risk in humans: a role for DNA methylation. Eur J Clin Invest. 2015;45(3): 303-32.
5. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9): 967-75.
6. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729-36.
7. Sheppard VB, Mays D, LaVeist T, Tercyak KP. Medical mistrust influences black women's level of engagement in BRCA 1/2 genetic counseling and testing. J Natl Med Assoc. 2013;105(1):17-22.
8. Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13(4):349-55.
9. Rauscher GH, Ferrans CE, Kaiser K, Campbell RT, Calhoun EE,Warnecke RB. Misconceptions about breast lumps and delayed medical presentation in urban breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19(3): 640-7.
10. Allford A, Qureshi N, Barwell J, Lewis C, Kai J.What hinders minority ethnic access to cancer genetics services and what may help? Eur J Hum Genet. 2014;22(7):866-74.
11. Thompson HS, Sussner K, Schwartz MD, Edwards T, Forman A, Jandorf L, et al. Receipt of genetic counseling recommendations among black women at high risk for BRCA mutations. Genet Test Mol Biomarkers. 2012;16(11):1257-62.
12. Shields AE, Burke W, Levy DE. Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med. 2008; 10(6):404-14.
13. Olaya W, Esquivel P, Wong JH, Morgan JW, Freeberg A, Roy-Chowdhury S, et al. Disparities in BRCA testing: when insurance coverage is not a barrier. Am J Surg. 2009;198(4):562-5.
14. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL, et al. Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities. Am J Public Health. 2008;98(9):1608-15.
15. Malen R, Knerr S, Delgado F, Fullerton SM, Thompson B. Rural Mexican-Americans' perceptions of family health history, genetics, and disease risk: implications for disparities-focused research dissemination. J Community Genet. 2015; 7(1):91-6.
16. Haffty BG, Silber A, Matloff E, Chung J, Lannin D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women. J Med Genet. 2006;43(2):133-7.
17. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52-62.
18. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
19. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283-98.
20. Hunter CP. Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations. Cancer. 2000;88(5, Suppl):1193-202.
21. Verma R, Bowen RL, Slater SE, Mihaimeed F, Jones JL. Pathological and epidemiological factors associated with advanced stage at diagnosis of breast cancer. Br Med Bull. 2012;103(1):129-45.
22. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancerspecific survival by race and ethnicity in the United States. JAMA. 2015; 313(2):165-73.
23. Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a populationbased study and first report. Cancer. 2010;116(11):2549-59.
24. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res. 2010;16(24):6100-10.
25. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population- based study from the California cancer registry. Cancer. 2007; 109(9):1721-8.
26. Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011;127(3):729-38.
27. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15(6):593-602.
28. Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003;22(1):55-65.
29. Cross CK, Harris J, Recht A. Race, socioeconomic status, and breast carcinoma in the U.S.: what have we learned from clinical studies. Cancer. 2002;95(9):1988-99.
30. Sineshaw HM, Gaudet M, Ward EM, Flanders WD, Desantis C, Lin CC, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). Breast Cancer Res Treat. 2014; 145(3):753-63.
31. Conway K, Edmiston SN, Tse CK, Bryant C, Kuan PF, Hair BY, et al. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2015; 24(6):921-30.
32. Guiu S, Michiels S, André F, Cortes J, Denkert C, DiLeo A, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol. 2012;23(12):2997-3006.
33. Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 2013;32(5):617-28.
34. Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. 2014;106(10):dju237.
35. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and metaanalysis. J Natl Cancer Inst. 2014; 106(8):dju091.
36. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841-5.
37. Easterling RE. Racial factors in the incidence and causation of end-stage renal disease (ESRD). Trans Am Soc Artif Intern Organs. 1977;23:28-33.
38. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med. 1982; 306(21):1276-9.
39. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14(11):2902-7.
40. Derose SF, Rutkowski MP, Crooks PW, Shi JM, Wang JQ, Kalantar-Zadeh K, et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis. 2013; 62(2):236-44.
41. Tzur S, Rosset S, Skorecki K, Wasser WG. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant. 2012;27(4): 1498-505.
42. Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, et al. A high-density admixture map for disease gene discovery in African Americans. Am J Hum Genet. 2004;74(5):1001-13.
43. Tin A, Grams M, Maruthur NM, Astor B, Couper D, Mosley TH, et al. Hemostatic factors, APOL1 risk variants, and the risk of end-stage renal disease in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol. 2015;10(5):784-90.
44. Matsha TE, Kengne AP, Masconi KL, Yako YY, Erasmus RT. APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans. BMC Genet. 2015;16:69.
45. Horowitz CR, Abul-Husn NS, Ellis S, Ramos MA, Negron R, Suprun M, et al. Determining the effects and challenges of incorporating genetic testing into primary care management of hypertensive patients with African ancestry. Contemp Clin Trials. 2016;47:101-8.
46. Thompson B, Molina Y, Viswanath K, Warnecke R, Prelip ML. Strategies to empower communities to reduce health disparities. Health Aff (Millwood). 2016;35(8):1424-29.
47. Simonds VW, Wallerstein N, Duran B, Villegas M. Community-based participatory research: its role in future cancer research and public health practice. Prev Chronic Dis. 2013;10:E78.